Literature DB >> 16965497

Non-penetrating deep sclerectomy for glaucoma associated with Sturge-Weber syndrome.

François Audren1, Olivia Abitbol, Pascal Dureau, Salim Hakiki, Christophe Orssaud, Marie Bourgeois, Alain Pierre-Kahn, Christine Bodemer, Jean-Louis Dufier.   

Abstract

PURPOSE: To report the results of non-penetrating deep sclerectomy (NPDS) in the treatment of glaucoma associated with Sturge-Weber syndrome (SWS).
METHODS: We carried out a retrospective case series analysis of patients who underwent NPDS for glaucoma associated with SWS between 1998 and 2003. The control of glaucoma after NPDS, the results of surgery on intraocular pressure, the need for additional medical treatment and surgical complications were studied.
RESULTS: Twelve eyes of nine patients, aged 11 days to 24 years, underwent filtering surgery: nine NPDS procedures were performed and three surgical procedures had to be converted to trabeculectomy because NPDS was not technically achievable. The mean follow-up after surgery was 26.3 months (range 6-48 months). Two trabeculectomies were complicated by choroidal effusion, which resolved in both cases. Good control of glaucoma was obtained during follow-up.
CONCLUSIONS: Non-penetrating deep sclerectomy is transiently efficient in the treatment of SWS-associated glaucoma. Further studies of NPDS for the treatment of glaucoma associated with SWS are warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16965497     DOI: 10.1111/j.1600-0420.2006.00723.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  12 in total

Review 1.  Pathophysiology, diagnosis, and management of glaucoma associated with Sturge-Weber syndrome.

Authors:  Usman Javaid; Muhammad Hassaan Ali; Samreen Jamal; Nadeem Hafeez Butt
Journal:  Int Ophthalmol       Date:  2017-01-07       Impact factor: 2.031

2.  Focal venous hypertension as a pathophysiologic mechanism for tissue hypertrophy, port-wine stains, the Sturge-Weber syndrome, and related disorders: proof of concept with novel hypothesis for underlying etiological cause (an American Ophthalmological Society thesis).

Authors:  Cameron F Parsa
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

3.  Surgical management of glaucoma secondary to idiopathic elevated episcleral venous pressure.

Authors:  Zia Sultan Pradhan; Ashish Kuruvilla; Pushpa Jacob
Journal:  Oman J Ophthalmol       Date:  2015 May-Aug

4.  Sturge-weber syndrome.

Authors:  Catherine D Bachur; Anne M Comi
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 5.  [Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Authors:  Roman Greslechner; Horst Helbig; Detlev Spiegel
Journal:  Ophthalmologe       Date:  2022-04-26       Impact factor: 1.059

6.  Incidence of Sturge-Weber syndrome and associated ocular involvement in Olmsted County, Minnesota, United States.

Authors:  Heba T Rihani; Lauren A Dalvin; David O Hodge; Jose S Pulido
Journal:  Ophthalmic Genet       Date:  2020-03-31       Impact factor: 1.803

7.  Congenital glaucoma from Sturge-Weber syndrome: a modified surgical approach.

Authors:  Nancy Shi Yin Yuen; Ian Yat Hin Wong
Journal:  Korean J Ophthalmol       Date:  2012-11-12

8.  Current surgical options for the management of pediatric glaucoma.

Authors:  Jose Morales; Sami Al Shahwan; Sami Al Odhayb; Ibrahim Al Jadaan; Deepak P Edward
Journal:  J Ophthalmol       Date:  2013-04-24       Impact factor: 1.909

9.  Primary single-plate Molteno tube implantation for management of glaucoma in children with Sturge-Weber syndrome.

Authors:  Heydar Amini; Mohammad Reza Razeghinejad; Bahare Esfandiarpour
Journal:  Int Ophthalmol       Date:  2007-06-08       Impact factor: 2.029

Review 10.  Pediatric Glaucoma: A Literature's Review and Analysis of Surgical Results.

Authors:  Gianluca Scuderi; Daniela Iacovello; Federica Pranno; Pasquale Plateroti; Luca Scuderi
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.